🔗 Visit the ClinicalTrials.gov page for NCT02008383
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. | World J Gastroenterol | 2016 | 0.87 |
| 2 | The treatment landscape in thyroid cancer: a focus on cabozantinib. | Cancer Manag Res | 2015 | 0.79 |
| 3 | Genomic diversity of colorectal cancer: Changing landscape and emerging targets. | World J Gastroenterol | 2016 | 0.75 |
| 4 | Colorectal clinical trials: what is on the horizon? | Future Oncol | 2016 | 0.75 |
| 5 | Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers. | Cancer Chemother Pharmacol | 2022 | 0.75 |